2016
The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality
Gaither JR, Goulet JL, Becker WC, Crystal S, Edelman EJ, Gordon K, Kerns RD, Rimland D, Skanderson M, Justice AC, Fiellin DA. The Effect of Substance Use Disorders on the Association Between Guideline-concordant Long-term Opioid Therapy and All-cause Mortality. Journal Of Addiction Medicine 2016, 10: 418-428. PMID: 27610580, PMCID: PMC5083184, DOI: 10.1097/adm.0000000000000255.Peer-Reviewed Original ResearchConceptsSubstance use disordersLong-term opioid therapyCause mortalityOpioid therapySUD treatmentUse disordersLower mortalityTime-updated Cox regressionUntreated substance use disordersVeterans Aging Cohort StudyOpioid-prescribing guidelinesGuideline-concordant careSUD statusAging Cohort StudyClinical practice guidelinesSUD treatment servicesOverall sampleHIV patientsCohort studyCox regressionPractice guidelinesPatientsTreatment servicesHigh mortalityMortality
2013
The Next Therapeutic Challenge in HIV: Polypharmacy
Edelman EJ, Gordon KS, Glover J, McNicholl IR, Fiellin DA, Justice AC. The Next Therapeutic Challenge in HIV: Polypharmacy. Drugs & Aging 2013, 30: 613-628. PMID: 23740523, PMCID: PMC3715685, DOI: 10.1007/s40266-013-0093-9.BooksConceptsAntiretroviral therapyHIV infectionSerious adverse drug eventsChronic antiretroviral therapyHarms of polypharmacyLifelong antiretroviral therapyRisk of polypharmacyCombination antiretroviral therapyNumber of medicationsAdverse drug eventsOrgan system injuryDecades of lifePhysiologic frailtyHIV patientsMore medicationsComorbid diseasesGeriatric syndromesImmune dysfunctionMedication adherenceMost HIVTherapeutic challengeChronic inflammationSystem injuryDrug eventsPolypharmacy